Navigation Links
Brigham and Women's Hospital awarded $9.6 million to study whole genome sequencing
Date:12/8/2011

Boston, MA Brigham and Women's Hospital (BWH) has been awarded $9.6 million over four years from the National Human Genome Research Institute (NHGRI) to fund the Medical Sequencing (MedSeq) Research Project. The MedSeq Project is the first clinical trial ever funded by NIH to empirically study the use of whole genome sequencing, the mapping of an individuals' entire DNA, in the practice of medicine.

The proposed project, led by a multi-disciplinary team of more than 40 scientists, will first design an informatics pipeline to interpret several million genetic variants from each patient, and generate clinical reports that will be meaningful to practicing physicians. After that, 200 patients and their physicians will be enrolled in a clinical trial where they will receive either standard care with whole genome sequencing or standard care without whole genome sequencing. Researchers will study two types of volunteers healthy middle-aged patients followed by primary care physicians and patients with newly diagnosed hereditary cardiomyopathy. The MedSeq Project will begin enrollment in 2012.

"This study will build on the expertise and accomplishments of this remarkable scientific team to create and test novel methods for interpreting whole genome sequencing information and actually using that information in clinical medicine," said Robert C. Green, MD, MPH, a physician-scientist in the Division of Genetics at BWH and overall director of the study. "This research will accelerate the use of genomics in clinical care, taking another step toward fulfilling the promise that genome sciences will usher in an era of personalized genetic medicine for the betterment of human health."

The first human genome was decoded through the Human Genome Project in 2003, however the use of individual sequencing in medical care is only beginning now, largely due to the falling costs of sequencing and bioinformatics advances. The MedSeq Project is the first clinical trial funded by NIH to support translating complicated genomic sequence data into understandable laboratory reports, and to evaluate how these reports will be used in a clinical setting.

"One of the most controversial issues the study team will face is whether to look for and whether to report 'incidental' genetic findings or mutations that suggest previously unsuspected genetic predisposition to cancer, heart disease or other conditions that are found in otherwise healthy individuals," Green said. "Reporting too many incidental results could generate unnecessary and costly medical tests, while reporting too few could deprive patients and doctors of valuable risk information."

In addition to Green, the research will be led by co-directors Mike Murray, MD, Christine Seidman, MD and Heidi Rehm, PhD from Brigham and Women's Hospital. As well as Amy McGuire, JD, PhD from Baylor College of Medicine and Zak Kohane, MD, PhD, from Children's Hospital Boston.

Speaking to the significance of the study, Kohane said, "medical practice and medical education by and large does not currently address the procedures and challenges of disclosing large-scale genomic data to patients. This grant will allow us to determine what part of the process needs refinement, where additional education of either the patient of physician will make for a more productive encounter, and how best to summarize this vast body of data in one all-to-brief clinical encounter."


'/>"/>

Contact: Tom Langford
tlangford@partners.org
617-534-1605
Brigham and Women's Hospital
Source:Eurekalert

Related biology news :

1. NIH awards $17 million Program of Excellence Award in glycosciences to Brigham and Womens Hospital
2. Brigham and Womens Hospital researcher named National Space Biomedical Research Institute Fellow
3. University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink
4. University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging
5. BUSM: Severe sepsis, new-onset AF associated with increased risk of hospital stroke, death
6. Childrens Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center
7. The Childrens Hospital of Philadelphia and BGI Announce Partnership and New Joint Genome Center to Target Pediatric Diseases
8. Study: Residential washers may not kill hospital-acquired bacteria
9. Researchers at Cruces Hospital describe new syndrome of slight family intellectual disability
10. Thomas Jefferson University Hospital adopts new automated laboratory
11. Mass. Eye and Ear awarded largest NIH grant in hospital’s history
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
Breaking Biology Technology: